Citius pharmaceuticals expands management team with appointment of kelly creighton, phd as executive vice president of chemistry, manufacturing and controls

Cranford, n.j., nov. 5, 2021 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran kelly creighton, phd as executive vice president of chemistry, manufacturing and controls (cmc).
CTXR Ratings Summary
CTXR Quant Ranking